An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (CAAA617D12302)
Oligometastatic Prostate Cancer
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Lingeswaran
drlinges79@gmail.com
03-77860846
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study
of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR Prostate01)
Hospital Pulau Pinang
PRINCIPAL INVESTIGATOR
Dr Fong Chin Heng
CONTACT
SC: Nurul Bisyarah Husna Abdul Aziz
Contact No – 6017 5322058
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Prof Marniza Saad
CONTACT
03-79492120
Hospital Sultan Ismail
PRINCIPAL INVESTIGATOR
Dr Vickee Rajeswaran
CONTACT
SC: Norhamiza Misri
Contact No – 6017 7229575
Hospital Umum Sarawak
PRINCIPAL INVESTIGATOR
Dr Hadi Ab Jalil
CONTACT
SC: Wee Wee Bt Buyong
Contact No – 6016 8582119
Hospital Wanita dan Kanak-Kanak Sabah (Likas)
PRINCIPAL INVESTIGATOR
Dr Aldrin Jasper Placidus
CONTACT
SC: Roslin Guadih
Contact No – 6016 8151234
Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
Dr Rufus Jesudass
CONTACT
SC: Norshahida Mohd Nawi
Contact No – 6018 9794124
A Phase 3 Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA003)
Sarawak Genaral Hospital Kuching (SGH)
PRINCIPAL INVESTIGATOR
DR HADI BIN AB.JALIL
hadiabjalil@gmail.com
CONTACT
SC: Wee Wee Buyong
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
National Cancer Institute Putrajaya (IKN)
PRINCIPAL INVESTIGATOR
Dr Suhana
CONTACT
SC: Shamiza
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03-8892 5622 (Fax)
Hospital Sultan Ismail Johor (HSI)
PRINCIPAL INVESTIGATOR
Dr Vickee
CONTACT
SC: Ezzah Aishah Najwa
General line : 07 – 356 5000
CRC: 07 – 356 5000 ext: 2408
Dr Munirah Admin Manager
drmunirah@hsi.gov.my
Hospital Kuala Lumpur (HKL)
PRINCIPAL INVESTIGATOR
Dr Sandya Subramaniam
CONTACT
SC: Nurul Aiman
University Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
AP Dr Marniza Saad
CONTACT
SC: Cryst Sari
Contact: 0379492120
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next generation Hormonal Agent (NHA)
(OMAHA 004)
Sarawak Genaral Hospital Kuching (SGH)
PRINCIPAL INVESTIGATOR
DR HADI BIN AB.JALIL
hadiabjalil@gmail.com
CONTACT
SC: Felicia
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
National Cancer Institute Putrajaya (IKN)
PRINCIPAL INVESTIGATOR
Dr Suhana
CONTACT
SC: Hadi
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03-8892 5622 (Fax)
Hospital Sultan Ismail Johor (HSI)
PRINCIPAL INVESTIGATOR
Dr Vickee
CONTACT
SC: Ezzah Aishah Najwa
General line : 07 – 356 5000
CRC: 07 – 356 5000 ext: 2408
Dr Munirah Admin Manager
drmunirah@hsi.gov.my
Hospital Kuala Lumpur (HKL)
PRINCIPAL INVESTIGATOR
Dr Sandya Subramaniam
CONTACT
SC: Nurul Aiman
University Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
AP Dr Marniza Saad
CONTACT
SC: Suganiya
Contact: 0379492120